Longboard Pharmaceuticals to Participate in the Cantor Neurology & Psychiatry Conference
September 29, 2022 16:01 ET
|
Longboard Pharmaceuticals, Inc.
SAN DIEGO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for...
Longboard Pharmaceuticals to Participate in Upcoming Investor Conferences
September 01, 2022 16:01 ET
|
Longboard Pharmaceuticals, Inc.
SAN DIEGO, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for...
Longboard Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2022 Financial Results
August 04, 2022 16:05 ET
|
Longboard Pharmaceuticals, Inc.
LP352 Phase 1b/2a PACIFIC Study remains on track for completion in the second half of 2023; recently expanded the participant age range to 12-65 years old and added open-label extension studyInitiated...
Longboard Pharmaceuticals to Present at the 2022 Wedbush PacGrow Healthcare Virtual Conference
August 03, 2022 08:30 ET
|
Longboard Pharmaceuticals, Inc.
SAN DIEGO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for...
Longboard Pharmaceuticals to Present at the JMP Securities 2022 Life Sciences Conference on June 15
June 07, 2022 08:30 ET
|
Longboard Pharmaceuticals, Inc.
SAN DIEGO, June 07, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for...
Longboard Pharmaceuticals to Participate in Five Upcoming Epilepsy-Focused Conferences this Summer
June 01, 2022 08:30 ET
|
Longboard Pharmaceuticals, Inc.
SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for...
Longboard Pharmaceuticals to Participate in Upcoming Investor Events
May 12, 2022 08:30 ET
|
Longboard Pharmaceuticals, Inc.
SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for...
Longboard Pharmaceuticals Provides Corporate Update and Reports First Quarter 2022 Financial Results
May 05, 2022 16:05 ET
|
Longboard Pharmaceuticals, Inc.
Phase 1 data for LP352, a potential treatment for seizures associated with a broad range of severe epilepsies, presented at the American Academy of Neurology (AAN) Annual MeetingInitiated Phase 1b/2a...
Longboard Pharmaceuticals to Present Phase 1 Data for LP352 at the American Academy of Neurology Annual Meeting
April 01, 2022 08:30 ET
|
Longboard Pharmaceuticals, Inc.
Two poster presentations highlight Phase 1 data for LP352 in healthy volunteers SAN DIEGO, April 01, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage...
Longboard Pharmaceuticals to Participate in Cantor Fitzgerald’s Virtual Rare Orphan Disease Summit
March 23, 2022 16:01 ET
|
Longboard Pharmaceuticals, Inc.
SAN DIEGO, March 23, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for...